| 2.26 -0.11 (-4.64%) | 06-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.08 | 1-year : | 3.6 |
| Resists | First : | 2.64 | Second : | 3.08 |
| Pivot price | 2.17 |
|||
| Supports | First : | 1.91 | Second : | 1.59 |
| MAs | MA(5) : | 2.18 |
MA(20) : | 2.23 |
| MA(100) : | 2.73 |
MA(250) : | 2.9 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 57.2 |
D(3) : | 42 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 6.19 | Low : | 1.66 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TCRT ] has closed below upper band by 29.0%. Bollinger Bands are 36.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.47 - 2.48 | 2.48 - 2.49 |
| Low: | 2.18 - 2.19 | 2.19 - 2.2 |
| Close: | 2.35 - 2.37 | 2.37 - 2.39 |
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
Mon, 29 Jun 2026
Alaunos Therapeutics (TCRT) posts new ALN1003 mouse liver and metabolic findings - Stock Titan
Fri, 26 Jun 2026
Alaunos Therapeutics, Inc. Actuals & Estimates (NASDAQ:TCRT) - TradingView
Thu, 18 Jun 2026
Alaunos Therapeutics Inc (TCRT) Institutional Confidence - TradingKey
Wed, 17 Jun 2026
Alaunos Therapeutics Inc (TCRT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Wed, 17 Jun 2026
Alaunos Therapeutics (TCRT) CEO takes 7,761-share stock grant in lieu of salary - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.9e+006 (%) |
| Held by Institutions | 14.3 (%) |
| Shares Short | 8 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.13e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -138 % |
| Return on Assets (ttm) | 166.6 % |
| Return on Equity (ttm) | -129.5 % |
| Qtrly Rev. Growth | 3000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0.5 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.89 |
| Dividend | 0 |
| Forward Dividend | 11610 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|